Business Trip

Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in a partnership with AbbVie worth up to $1.2B. In this episode, we discuss: • Why Gilgamesh is building psychedelic medicines the way large pharma would • The thesis behind short-acting psychedelics and why long-duration trips are impractical...

Greg speaks with three leaders in mental health philanthropy: Alyson Nieman from Mindful Philanthropy, Sabrina Gracias from Ortus Foundation, and Christena Huntsman Durham from Huntsman Mental Health Foundation, each offering a distinct perspective on how funding decisions get made and where the biggest gaps remain. In this episode we discuss: Trends in mental health philanthropy, and the 10-year challenge: how the field moves from roughly $2B to $35B in annual funding.Funding the clinic of t...

Greg interviews Rick Perry, the former Governor of Texas and former U.S. Secretary of Energy and leading advocate for ibogaine, live at the Real Summit. In this episode, we discuss: How a former Texas governor moved from strict opposition to drugs to becoming a leading advocate for ibogaine after firsthand experience and veteran outcomes.Ibogaine’s impact on PTSD, opioid addiction, and traumatic brain injury, including Stanford-linked brain imaging data showing functional and structural impro...

Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS. In this episode, we discuss: Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs acr...

Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery. In this episode, we discuss: How LLMs expand the scope of machine learning from rule-based tasks to open-ended reasoning and dialogueWhy healthcare adoption is tiered, beginning with clinician-facing AI scribes and moving toward patient-facing companies...